Scilex Holding Company announced completion of its SP-103 Phase 2 study to evaluate the safety and efficacy in subjects with acute LBP. The Phase 2, randomized, double-blind, placebo-controlled, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback